Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 31, 1999 - Issue 6
Submit an article Journal homepage
27
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Calibration of Disk Diffusion Antibiotic Susceptibility Testing: Species-related Trovafloxacin Interpretive Zone Breakpoints and Selection of Disk Potency

Göran Kronvall, Margareta Rylander, Mats Walder, Lena Lind-Brandberg, Peter Larsson, Eva Törnqvist, Tor Monsen Clinical Microbiology L2:02, Department of Laboratory Medicine, Karolinska Hospital, SE-171 76 Stockholm, Sweden
Pages 573-578 | Published online: 08 Jul 2009

  • Kronvall G. Analysis of a single reference strain for determination of gentamicin regression line constants and inhibition zone diameter breakpoints in quality control of disk diffusion antibiotic susceptibility testing. J Clin Microbiol 1982; 16: 784–93.
  • Björklind A, Ringertz S, Kronvall G. Types of interpretive errors in susceptibility testing. APMIS 1989; 97: 941–8.
  • Kronvall G, Ringertz S. Antibiotic disk diffusion testing revisited. Single strain regression analysis. Review article. APMIS 1991; 99: 295–306.
  • Kronvall G, Ringertz S, Karlsson I, Göransson E, Dornbusch K. Laboratory- and species-specific interpretive breakpoints for disk diffusion tests of chloramphenicol susceptibility of Haemophilus influenzae. Antimicrob Ag Chemother 1988; 32: 1484–9.
  • Ringertz S, Björklind A, Kronvall G. Species-specific interpretive breakpoints for ciprofloxacin disk diffusion susceptibility testing. Scand J Infect Dis 1989; Suppl 60: 46–53.
  • Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997; 39: 1–14.
  • Gooding BB, Jones RN. In vitro Antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Ag Chemother 1993; 37: 349–53.
  • Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering Jr RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Ag Chemother 1993; 37: 366–70.
  • Sefton AM, Maskell JP, Seymour AC, Minassian M, Williams JD. Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens. J Antimicrob Chemother 1996; 37: 803–8.
  • Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869–76.
  • Verbist L, Verhaegen J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur J Clin Microbiol Infect Dis 1996; 15: 683–5.
  • Rylander M, Walder M, Lind-Brandberg L, Larsson P, Törnqvist E, Monsen T, et al. Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden. Scand Infect Dis 1999; 31: 567–72.
  • Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis 1997; Suppl 105: 13–23.
  • Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis 1997; Suppl 105: 8–12.
  • Kronvall G. Response to Drs Ian Phillips and Anna King. Clin Microbiol Infect 1998; 4: 232.
  • O’Brien TF, Kent RL, Medeiros AA. Computer-generated plots of results of antimicrobial-susceptibility tests. JAMA 1969; 210: 84–92.
  • Ericsson HM. Standardization of methods for conducting microbic sensitivity tests. Stockholm: Karolinska Sjukhuset, 1964: 1.
  • Forsberg P, Petersson AC, Kronvall G. Determination of species-and laboratory-related interpretive breakpoints for doxycycline susceptibility testing using single-strain regression analysis. Acta Path Microbiol Immunol Scand Sect B 1985; 93: 53–60.
  • Kronvall G, Runehagen A. Förbättrad känslighetsbedömning av bakterier medelst artrelaterat SIR-system (Improved determination of antibiotic susceptibility of bacteria using species-related SIR interpretation). Läkartidningen 1981; 78: 3483–5.
  • Schmalreck AF, Kottmann I, Reiser A, et al. In vitro testing of trovafloxacin according to the DIN 58940 guidelines: evaluation of trovafloxacin discs and proposal of tentative DIN breakpoints. Abstract No P403. Clin Microbiol Infect 1997; 3 Suppl 2: 91
  • Fuchs PC, Barry AL, Brown SD, Sewell DL. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis 1996; 15: 678–82.
  • Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130: 588–94.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.